Terminal

“Of course they will ask questions,” Ms. Richmond said. “Once again, I must remind you that this could ruin everything we’ve worked for.”

“You don’t have to tell me,” Dr. Mason said.

“Well, what are you going to do?”

“I don’t know what else to do,” Dr. Mason admitted. “Let’s get Harris up here.”

Dr. Mason had Patty call Robert Harris and told her to buzz him the moment Harris arrived. “I have Sterling Rombauer in my office,” he told Ms. Richmond. “Maybe you should hear what he has to say about our medical student extern.”

“That brat!” Ms. Richmond said. “When I caught him over in the hospital sneaking a look at Helen Cabot’s chart I felt like throttling him.”

“Calm down and come in and listen,” Dr. Mason said.

Ms. Richmond reluctantly allowed Dr. Mason to lead her into his office. Sterling got to his feet. Ms. Richmond told him he didn’t have to stand on her account.

Dr. Mason had everybody sit, then asked Sterling to bring Ms. Richmond up to date.

“Sean Murphy is an interesting and complicated individual,” Sterling said as he casually crossed his legs. “He’s lived a rather double life, changing drastically when he got into Harvard undergraduate school, yet still clinging to his blue-collar Irish roots. And he’s been successful. Currently he and a group of friends are about to start a company they intend to call Oncogen. Its goal will be to market diagnostic and therapeutic agents based on oncogene technology.”

“Then it’s clear what we should do,” Ms. Richmond said. “Especially considering his being insufferably brash.”

“Let Sterling finish,” Dr. Mason said.

“He’s extremely bright when it comes to biotechnology,” Sterling said. “In fact I’d have to say he’s gifted. His only real liability, as you’ve already guessed, is in the social realm. He has little respect for authority and manages to irritate a lot of people. That said, he’s already been involved with the founding of a successful company that was bought out by Genentech. And he’s had no significant difficulty finding funding for his second venture.”

“He’s sounding more and more like trouble,” Ms. Richmond said.

“Not in the way you think,” Sterling said. “The problem is that Sushita knows approximately as much as I do. It’s my professional opinion that they will deem Sean Murphy a threat to their investment here at Forbes. Once they do, they’ll be inspired to act. I’m not convinced a move to Tokyo and, essentially, a buyout, will work with Mr. Murphy. Yet if he stays here, I think they’ll consider reneging on renewing your grant.”

“I still don’t understand why we don’t send him back to Boston,” Ms. Richmond said. “Then it’s over. Why take the risk of jeopardizing our relationship with Sushita?”

Sterling looked at Dr. Mason.

Dr. Mason cleared his throat. “From my perspective,” he said, “I don’t want to be rash. The kid is good at what he does. This morning I went down to where he’s working. He’s got a whole generation of mice accepting the glycoprotein. On top of that, he showed me some promising crystals that he’s been able to grow. He insists he’ll have better in a week. No one else has been able to get this far. My problem is I’m caught between a rock and a hard place. A more dire threat to our Sushita funding is the fact that we have yet to provide them with a single patentable product. They expected something by now.”

“In other words, you think we need this brat even with the risks,” Ms. Richmond said.

“That’s not the way I would phrase it,” Dr. Mason said.

“Then why don’t you call Sushita and explain it to them,” Ms. Richmond said.

“That would not be advisable,” Sterling said. “The Japanese prefer indirect communication so that confrontation can be avoided. They would not understand such a direct approach. Such a ploy would cause more anxiety than it would alleviate.”

“Besides, I already alluded to all this with Hiroshi,” Dr. Mason said. “And they still went ahead to investigate Mr. Murphy on their own.”

“The Japanese businessman has a great problem with uncertainty,” Sterling added.

“So what is your take on this kid?” Ms. Richmond asked. “Is he a spy? Is that why he’s here?”

“No,” Sterling said. “Not in any traditional sense. He’s obviously interested in your success with medulloblastoma, but it’s from an academic point of view, not a commercial one.”

“He was very open about his interests in the medulloblastoma work,” Dr. Mason said. “The first time I met him he was clearly disappointed when I informed him he would not be permitted to work on the project. If he’d been some kind of spy, I think he’d keep a lower profile. Rocking the boat only draws further scrutiny.”

“I agree,” Sterling said. “As a young man he’s still motivated by idealism and altruism. He has not yet been poisoned by the new commercialism of science in general and medical research in particular.”

“Yet he’s already started his own company,” Ms. Richmond pointed out. “That sounds pretty commercial to me.”